Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

LAMEA Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026

Published by KBV Research Product code 988485
Published Content info 68 Pages
Delivery time: 1-2 business days
Price
Back to Top
LAMEA Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026
Published: January 29, 2021 Content info: 68 Pages
Description

The Latin America, Middle East and Africa Biodefense Market would witness market growth of 6.7% CAGR during the forecast period (2020-2026).

Biodefense is referred to the exhaustive steps (identification, planning, and preparedness) employed to re-establish the biosecurity of a nation with respect to biological threats or infectious diseases. Also, these weapons can be used to initiate bioterrorism and social upheaval. The origin of biological threats could be accidental, deliberate, or naturally occurring. Supportive government initiatives, huge investment by private players, and the increasing prevalence of different viral agents are some of the major factors boosting the market growth.

Increased awareness about bioterrorism attacks in various developed economies, will fuel the development of the global biodefense market over the forecast period. These attacks are considered as the process of intentional release of bacteria, viruses, and other harmful microbes, that are capable of bring devastation.

Such a situation creates a destructive impact on the economy and human life & health. Moreover, it results in the depletion of human resources. Due to this scenario, the government in the developed economies undertakes various initiatives coupled with preventive measures to manage these attacks. This factor is anticipated to encourage the growth of the biodefense market during the forecast period.

Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.

Scope of the Study

Market Segmentation:

By Product

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/nuclear,
  • Other Products

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • Xoma Corporation
  • Altimmune, Inc.
  • Emergent BioSolutions, Inc.
  • Dynavax Technologies Corporation
  • SIGA Technologies, Inc.
  • Elusys Therapeutics, Inc.
  • Ichor Holdings, Ltd.
  • Cleveland BioLabs, Inc.
  • Bavarian Nordic A/S
  • Alnylam Pharmaceuticals, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Biodefense Market, by Product
    • 1.4.2 LAMEA Biodefense Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 Recent Industry Wide Strategic Developments
    • 3.1.1 Partnerships, Collaborations and Agreements
    • 3.1.2 Approvals
    • 3.1.3 Acquisition and Mergers
  • 3.2 Top Winning Strategies
    • 3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players

Chapter 4. LAMEA Biodefense Market by Product

  • 4.1 LAMEA Anthrax Market by Country
  • 4.2 LAMEA Smallpox Market by Country
  • 4.3 LAMEA Botulism Market by Country
  • 4.4 LAMEA Radiation/nuclear Market by Country
  • 4.5 LAMEA Other Product Market by Country

Chapter 5. LAMEA Biodefense Market by Country

  • 5.1 Brazil Biodefense Market
    • 5.1.1 Brazil Biodefense Market by Product
  • 5.2 Argentina Biodefense Market
    • 5.2.1 Argentina Biodefense Market by Product
  • 5.3 UAE Biodefense Market
    • 5.3.1 UAE Biodefense Market by Product
  • 5.4 Saudi Arabia Biodefense Market
    • 5.4.1 Saudi Arabia Biodefense Market by Product
  • 5.5 South Africa Biodefense Market
    • 5.5.1 South Africa Biodefense Market by Product
  • 5.6 Nigeria Biodefense Market
    • 5.6.1 Nigeria Biodefense Market by Product
  • 5.7 Rest of LAMEA Biodefense Market
    • 5.7.1 Rest of LAMEA Biodefense Market by Product

Chapter 6. Company Profiles

  • 6.1 Xoma Corporation
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Altimmune, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Research & Development Expense
    • 6.2.4 Recent strategies and developments:
      • 6.2.4.1 Acquisition and Mergers:
      • 6.2.4.2 Partnerships, Collaborations, and Agreements:
  • 6.3 Emergent BioSolutions, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Research & Development Expense
    • 6.3.4 Recent strategies and developments:
      • 6.3.4.1 Acquisition and Mergers:
      • 6.3.4.2 Partnerships, Collaborations, and Agreements:
  • 6.4 Dynavax Technologies Corporation
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Research & Development Expense
  • 6.5 SIGA Technologies, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Research & Development Expense
    • 6.5.4 Recent strategies and developments:
      • 6.5.4.1 Partnerships, Collaborations, and Agreements:
      • 6.5.4.2 Approvals:
  • 6.6 Elusys Therapeutics, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Recent strategies and developments:
      • 6.6.2.1 Approvals:
  • 6.7 Ichor Holdings, Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Partnerships, Collaborations, and Agreements:
  • 6.8 Cleveland BioLabs, Inc.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Research & Development Expense
    • 6.8.4 Recent strategies and developments:
      • 6.8.4.1 Partnerships, Collaborations, and Agreements:
  • 6.9 Bavarian Nordic A/S
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Partnerships, Collaborations, and Agreements:
      • 6.9.5.2 Approvals:
  • 6.10. Alnylam Pharmaceuticals, Inc.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Research & Development Expense

LIST OF TABLES

  • TABLE 1 LAMEA Biodefense Market, 2016 - 2019, USD Million
  • TABLE 2 LAMEA Biodefense Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Biodefense Market
  • TABLE 4 Approvals- Biodefense Market
  • TABLE 5 Acquisition and Mergers- Biodefense Market
  • TABLE 6 LAMEA Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 7 LAMEA Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 8 LAMEA Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 9 LAMEA Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 10 LAMEA Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 11 LAMEA Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 12 LAMEA Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 13 LAMEA Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 14 LAMEA Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 15 LAMEA Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 16 LAMEA Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 17 LAMEA Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 18 LAMEA Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 19 LAMEA Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 20 Brazil Biodefense Market, 2016 - 2019, USD Million
  • TABLE 21 Brazil Biodefense Market, 2020 - 2026, USD Million
  • TABLE 22 Brazil Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 23 Brazil Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 24 Argentina Biodefense Market, 2016 - 2019, USD Million
  • TABLE 25 Argentina Biodefense Market, 2020 - 2026, USD Million
  • TABLE 26 Argentina Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 27 Argentina Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 28 UAE Biodefense Market, 2016 - 2019, USD Million
  • TABLE 29 UAE Biodefense Market, 2020 - 2026, USD Million
  • TABLE 30 UAE Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 31 UAE Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 32 Saudi Arabia Biodefense Market, 2016 - 2019, USD Million
  • TABLE 33 Saudi Arabia Biodefense Market, 2020 - 2026, USD Million
  • TABLE 34 Saudi Arabia Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 35 Saudi Arabia Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 36 South Africa Biodefense Market, 2016 - 2019, USD Million
  • TABLE 37 South Africa Biodefense Market, 2020 - 2026, USD Million
  • TABLE 38 South Africa Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 39 South Africa Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 40 Nigeria Biodefense Market, 2016 - 2019, USD Million
  • TABLE 41 Nigeria Biodefense Market, 2020 - 2026, USD Million
  • TABLE 42 Nigeria Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 43 Nigeria Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 44 Rest of LAMEA Biodefense Market, 2016 - 2019, USD Million
  • TABLE 45 Rest of LAMEA Biodefense Market, 2020 - 2026, USD Million
  • TABLE 46 Rest of LAMEA Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 47 Rest of LAMEA Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 48 Key Information -Xoma Corporation
  • TABLE 49 Key Information - Altimmune, Inc.
  • TABLE 50 Key Information - Emergent BioSolutions, Inc.
  • TABLE 51 Key Information - Dynavax Technologies Corporation
  • TABLE 52 Key Information - SIGA Technologies, Inc.
  • TABLE 53 key information - Elusys Therapeutics, Inc.
  • TABLE 54 key Information - Ichor Holdings, Ltd.
  • TABLE 55 Key Information - Cleveland BioLabs, Inc.
  • TABLE 56 key information - Bavarian Nordic A/S
  • TABLE 57 Key Information - Alnylam Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players
  • FIG 4 Recent strategies and developments: Altimmune, Inc.
  • FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.
Back to Top